hydrochlorothiazide has been researched along with Prediabetes in 7 studies
Hydrochlorothiazide: A thiazide diuretic often considered the prototypical member of this class. It reduces the reabsorption of electrolytes from the renal tubules. This results in increased excretion of water and electrolytes, including sodium, potassium, chloride, and magnesium. It is used in the treatment of several disorders including edema, hypertension, diabetes insipidus, and hypoparathyroidism.
hydrochlorothiazide : A benzothiadiazine that is 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide substituted by a chloro group at position 6 and a sulfonamide at 7. It is diuretic used for the treatment of hypertension and congestive heart failure.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hypertensive patients with the cardiometabolic syndrome (CMS) are at increased risk for type 2 diabetes and cardiovascular disease." | 2.73 | Metabolic and antihypertensive effects of combined angiotensin receptor blocker and diuretic therapy in prediabetic hypertensive patients with the cardiometabolic syndrome. ( Deedwania, PC; Fonseca, VA; Haffner, SM; Hsueh, WA; Keeling, L; Sica, DA; Sowers, JR; Zappe, DH, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (57.14) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zappe, DH | 2 |
| Sowers, JR | 3 |
| Hsueh, WA | 1 |
| Haffner, SM | 1 |
| Deedwania, PC | 1 |
| Fonseca, VA | 1 |
| Keeling, L | 1 |
| Sica, DA | 1 |
| Ofili, EO | 1 |
| Purkayastha, D | 1 |
| Samuel, R | 1 |
| Wales, JK | 1 |
| Viktora, JK | 1 |
| Wolff, FW | 1 |
| Byington, RP | 1 |
| Furberg, CD | 1 |
| Craven, TE | 1 |
| Pahor, M | 1 |
| Nath, K | 1 |
| Sikka, KK | 1 |
| Saxena, S | 1 |
| Tandon, AP | 1 |
| Kocí, V | 1 |
| Drásilová, L | 1 |
| el-Ebrashy, N | 1 |
| el-Danasoury, M | 1 |
| Higazi, AM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A 16 Week Study to Evaluate the Effect on Insulin Sensitivity of Valsartan and Hydrochlorothiazide Combined and Alone, in Patients With Metabolic Syndrome[NCT00170937] | Phase 4 | 507 participants | Interventional | 2004-11-30 | Completed | ||
| A 16-week Double-blind, Randomized, Multicenter, Force-titration Study to Evaluate the Antihypertensive Efficacy of Valsartan/Hydrochlorothiazide (HCTZ) Therapy Compared to HCTZ Based Therapy in Obese, Hypertensive Patients[NCT00439738] | Phase 4 | 412 participants (Actual) | Interventional | 2006-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
After a 75 gram anhydrous glucose challenge 2 hours after an oral glucose tolerance test (NCT00439738)
Timeframe: Week 16
| Intervention | mg/dL (Mean) | |||||
|---|---|---|---|---|---|---|
| Baseline visit (0 minutes) | Week 16 (0 minutes) | Change from baseline to week 16 (0 minutes) | Baseline visit (120 minutes) | Week 16 (120 minutes) | Change from baseline to week 16 (120 minutes) | |
| HCTZ +Amlodipine | 99.4 | 102.8 | 3.4 | 127.7 | 146.5 | 18.9 |
| Valsartan/HCTZ (Hydrochlorothiazide) | 98.0 | 98.1 | -0.5 | 123.9 | 126.3 | 2.1 |
After a 75 gram anhydrous glucose challenge 2 hours after an oral glucose tolerance test (NCT00439738)
Timeframe: Week 16
| Intervention | mg/dL (Mean) | |||||
|---|---|---|---|---|---|---|
| Baseline visit (0 minutes) | Week 16 (0 minutes) | Change from baseline to week 16 (0 minutes) | Baseline visit (120 minutes) | Week 16 (120 minutes) | Change from baseline to week 16 (120 minute) | |
| HCTZ +Amlodipine | 20.37 | 23.62 | 3.67 | 95.95 | 120.01 | 28.07 |
| Valsartan/HCTZ (Hydrochlorothiazide) | 19.66 | 23.45 | 3.41 | 92.04 | 116.04 | 24.68 |
After a 75 gram anhydrous glucose challenge 2 hours after an oral glucose tolerance test (NCT00439738)
Timeframe: Week 16
| Intervention | mg/dL (Mean) | |||||
|---|---|---|---|---|---|---|
| Baseline visit (0 minutes) | Week 16 (0 minutes) | Change from baseline to week 16 (0 minutes) | Baseline visit (120 minutes) | Week 16 (120 minutes) | Change from baseline to week 16 (120 minutes) | |
| HCTZ +Amlodipine | 0.47 | 0.47 | 0.00 | 0.10 | 0.10 | -0.01 |
| Valsartan/HCTZ (Hydrochlorothiazide) | 0.45 | 0.46 | 0.01 | 0.11 | 0.10 | -0.01 |
(NCT00439738)
Timeframe: Baseline to Weeks 4, 8, 12 and 16
| Intervention | mm Hg (Mean) | |||||
|---|---|---|---|---|---|---|
| Baseline | Week 4 | Week 8 | Week 12 | Week 16 | Change from baseline to week 16 | |
| HCTZ +Amlodipine | 93.6 | 87.6 | 85.1 | 82.8 | 80.9 | -12.7 |
| Valsartan/HCTZ (Hydrochlorothiazide) | 94.9 | 85.7 | 81.9 | 81.1 | 80.8 | -14.0 |
(NCT00439738)
Timeframe: Baseline to Week 8
| Intervention | mm Hg (Mean) | ||
|---|---|---|---|
| Baseline | Week 8 | Change from baseline | |
| HCTZ +Amlodipine | 159.0 | 137.5 | -21.5 |
| Valsartan/HCTZ (Hydrochlorothiazide) | 159.7 | 131.2 | -28.6 |
Mean sitting systolic blood pressure/mean sitting diastolic blood pressure < 140/90 mm Hg (NCT00439738)
Timeframe: Weeks 4, 8, 12 16 and End of Study (for patients that did not complete the last visit at week 16)
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Week 4 | Week 8 | Week 12 | Week 16 | End of study | |
| HCTZ +Amlodipine | 69 | 102 | 112 | 140 | 146 |
| Valsartan/HCTZ (Hydrochlorothiazide) | 91 | 123 | 122 | 124 | 133 |
Mean sitting systolic blood pressure/mean sitting diastolic blood pressure < 130/80 mm Hg (NCT00439738)
Timeframe: Week 4, 8, 12, 16, End of Study (for patients that did not complete the last visit at week 16)
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Week 4 | Week 8 | Week 12 | Week 16 | End of Study | |
| HCTZ +Amlodipine | 18 | 23 | 46 | 65 | 68 |
| Valsartan/HCTZ (Hydrochlorothiazide) | 33 | 59 | 57 | 62 | 68 |
4 trials available for hydrochlorothiazide and Prediabetes
| Article | Year |
|---|---|
Metabolic and antihypertensive effects of combined angiotensin receptor blocker and diuretic therapy in prediabetic hypertensive patients with the cardiometabolic syndrome.
Topics: Adolescent; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Diabetes | 2008 |
Antihypertensive and metabolic effects of Angiotensin receptor blocker/diuretic combination therapy in obese, hypertensive African American and white patients.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensiv | 2013 |
The effect of hydrochlorothiazide in normal subjects receiving high fat or high carbohydrate diets.
Topics: Blood Glucose; Dietary Carbohydrates; Dietary Fats; Diuretics; Fatty Acids, Nonesterified; Female; G | 1967 |
Isradipine in prediabetic hypertensive subjects.
Topics: Antihypertensive Agents; Blood Glucose; Blood Pressure; Calcium Channel Blockers; Cardiovascular Dis | 1998 |
3 other studies available for hydrochlorothiazide and Prediabetes
| Article | Year |
|---|---|
Effect of thiazides on blood sugar level in oedematous and non oedematous states.
Topics: Adult; Bendroflumethiazide; Benzothiadiazines; Blood Glucose; Diabetes Mellitus; Diuretics; Edema; F | 1972 |
[Contribution to the problem of the diabetogenic effect of thiazide diuretics].
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus; Female; Humans; Hydrochlorothiazide; Middle Aged; Obe | 1969 |
Hyperuricaemic and hyperglycaemic effects of thiazides in non-prediabetics.
Topics: Blood; Diabetes Mellitus; Heart Failure; Humans; Hydrochlorothiazide; Polythiazide; Prediabetic Stat | 1965 |